Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Jazz Pharmaceuticals

    NASDAQ: JAZZ · Real-Time Price · USD
    117.19
    0.23 (0.20%)
    At close: May 01, 2025, 3:59 PM
    118.18
    0.84%
    Pre-market: May 02, 2025, 06:33 AM EDT

    Jazz Pharmaceuticals Revenue Breakdown

    Period Ending Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014 Dec 31, 2013 Sep 30, 2013 Jun 30, 2013 Mar 31, 2013 Dec 31, 2012 Sep 30, 2012 Jun 30, 2012 Mar 31, 2012
    Defitelio/Defibrotide Revenue 65.82M 45.42M 47.68M 46.11M 39.08M 40.65M 49.45M 54.7M 49.49M 42.51M 57.7M 48.1M 49.62M 55.45M 50.24M 42.71M 47.43M 47.78M 37.6M 46.05M 41.5M 37.71M 36.18M 4M 6.03M 3.44M 6.07M 6.71M 6.35M 8.1M 251.75M 242.9M 247.85M 212.69M 222.5M 204.34M 191.37M 160.38M 164.18M 153.66M 133.74M 117.53M 113.51M 102.61M 89.1M 73.44M
    Defitelio/Defibrotide Revenue Growth +44.91% -4.73% +3.40% +17.99% -3.87% -17.79% -9.59% +10.52% +16.41% -26.33% +19.98% -3.07% -10.52% +10.38% +17.62% -9.95% -0.73% +27.06% -18.35% +10.98% +10.04% +4.24% +803.52% -33.58% +75.49% -43.37% -9.61% +5.73% -21.65% -96.78% +3.64% -2.00% +16.53% -4.41% +8.89% +6.78% +19.32% -2.32% +6.84% +14.90% +13.80% +3.53% +10.62% +15.17% +21.32% n/a
    Epidiolex/Epidyolex Revenue 251.56M 247.1M 198.72M 202.23M 188.91M 207M 196.22M 175.29M 157.89M 193.79M 160.38M 109.48M 2.78M 1.6M 1.87M 852K 2.52M 4.23M 4.48M 5.17M 3.67M 4.91M 3.81M 27.95M 26.23M 24.07M 9.72M 298.03M 272.33M 291.2M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Epidiolex/Epidyolex Revenue Growth +1.80% +24.35% -1.74% +7.05% -8.74% +5.49% +11.94% +11.02% -18.52% +20.83% +46.49% +3833.92% +74.37% -14.74% +119.72% -66.22% -40.34% -5.67% -13.36% +40.85% -25.20% +29.01% -86.39% +6.57% +8.96% +147.67% -96.74% +9.44% -6.48% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Other Products Revenue 2.23M 2.7M 3.57M 3.42M 3.43M 3.07M 1M 1.63M 943K 1.03M 3.34M 2.64M 603.53M 661.3M 596.95M 26.57M 32.72M 31.52M 29.58M 31.36M 28.94M 25.62M 21.04M 356.01M 316.78M 312.48M 303.87M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Other Products Revenue Growth -17.38% -24.43% +4.48% -0.50% +11.97% +206.39% -38.66% +73.06% -8.45% -69.20% +26.62% -99.56% -8.74% +10.78% +2146.87% -18.80% +3.80% +6.56% -5.68% +8.36% +12.98% +21.77% -94.09% +12.38% +1.38% +2.83% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Product And Services, Product Sales Net Of Deductions Revenue 989.71M 964.14M 842.1M 946.99M 884.22M 967.53M 935.77M 928.3M 809.84M 892.88M 834.25M 748.34M 33.16M 30.99M 30.82M 446.81M 407.88M 435.35M 425.64M 413.21M 368.32M 374.83M 357.25M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Product And Services, Product Sales Net Of Deductions Revenue Growth +2.65% +14.49% -11.08% +7.10% -8.61% +3.39% +0.80% +14.63% -9.30% +7.03% +11.48% +2157.10% +6.98% +0.54% -93.10% +9.55% -6.31% +2.28% +3.01% +12.19% -1.74% +4.92% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Sativex Revenue 4.59M 6.38M 2.73M 2.81M 7.1M 4.72M 3.22M 4.14M 4.74M 4.65M 6.1M 1.96M 335.55M 439.27M 447.81M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Sativex Revenue Growth -28.15% +133.38% -2.53% -60.47% +50.35% +46.61% -22.26% -12.65% +2.00% -23.75% +210.91% -99.42% -23.61% -1.91% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Total Oncology Revenue 284.75M 277.31M 257.55M 252.21M 228.89M 30.27M 30.07M 33.89M 33.76M 34.76M 34.69M 31.45M 75.42M 53.44M 36.94M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Total Oncology Revenue Growth +2.68% +7.67% +2.12% +10.19% +656.25% +0.66% -11.28% +0.39% -2.90% +0.22% +10.29% -58.29% +41.13% +44.66% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Vyxeos Revenue 34.31M 43.01M 32.02M 34.06M 36.7M 247.5M 256.04M 269.42M 247.5M 288.76M 307.33M 334.18M 54.33M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Vyxeos Revenue Growth -20.22% +34.32% -5.97% -7.20% -85.17% -3.34% -4.97% +8.86% -14.29% -6.04% -8.03% +515.05% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Xyrem Revenue 58.11M 62.18M 64.23M 159.77M 178.13M 281.38M 255.94M 235.03M 186.08M 182.65M 153.06M 124.16M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Xyrem Revenue Growth -6.54% -3.19% -59.80% -10.31% -36.70% +9.94% +8.90% +26.30% +1.88% +19.33% +23.27% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Xywav Revenue 388.47M 368.47M 315.3M 326.56M 277.76M 71.97M 70.32M 68.28M 59.34M 64.84M 71.71M 55.92M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Xywav Revenue Growth +5.43% +16.86% -3.45% +17.57% +285.95% +2.34% +2.98% +15.08% -8.48% -9.59% +28.23% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Zepzelca Revenue 85.84M 81.05M 75.1M 70.35M 67.18M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Zepzelca Revenue Growth +5.92% +7.92% +6.75% +4.71% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a

    Revenue by Geography

    Period Ending Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013 Dec 31, 2012 Dec 31, 2011
    Europe Revenue 239.64M 230.16M 175.21M 150.2M 125.91M 122.79M 106.15M 103.61M 126.72M 61.84M 38.59M 6.22M
    Europe Revenue Growth +4.12% +31.36% +16.65% +19.29% +2.54% +15.68% +2.44% -18.23% +104.90% +60.26% +520.02% n/a
    Other Countries Revenue 49.36M 43.84M 43.82M 46.24M 37.44M 32.45M 26.91M 28.31M 1.01B 792.52M n/a n/a
    Other Countries Revenue Growth +12.59% +0.05% -5.24% +23.53% +15.37% +20.59% -4.96% -97.19% +27.11% n/a n/a n/a
    United States Revenue 3.37B 2.82B 2.14B 1.97B 1.73B 1.46B 1.35B 1.19B n/a n/a n/a n/a
    United States Revenue Growth +19.51% +31.51% +9.12% +13.76% +18.05% +8.01% +13.58% n/a n/a n/a n/a n/a

    Operating Expense Breakdown

    Period Ending Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
    Selling, General, and Administrative Revenue 325.77M 338.52M 351.71M 334.31M 308.31M 340.84M 297.92M 383.2M 358.48M 366.47M 308.81M 398.46M 363.68M 429.03M 260.51M 247.17M 207.25M 191.41M 208.4M 214.28M 178.71M 176.01M 167.95M 161.87M 155.87M 158.58M 207.21M 143.05M 124.52M 132.33M 144.25M 127.14M 124.37M 122.62M 128.76M 125.56M 104.04M 107.13M 112.39M
    Selling, General, and Administrative Revenue Growth -3.77% -3.75% +5.21% +8.43% -9.55% +14.41% -22.26% +6.90% -2.18% +18.67% -22.50% +9.56% -15.23% +64.69% +5.40% +19.26% +8.28% -8.15% -2.74% +19.90% +1.53% +4.80% +3.76% +3.84% -1.71% -23.47% +44.85% +14.88% -5.90% -8.27% +13.46% +2.23% +1.43% -4.77% +2.56% +20.67% -2.88% -4.68% n/a
    Research and Development Revenue 199.92M 220.73M 222.85M 216.61M 234.4M 209.24M 189.41M 172.56M 148.87M 139.05M 129.98M 155.44M 141.04M 132.7M 76.57M 91.7M 78.65M 78.92M 86.11M 97.38M 79.86M 62.38M 60.1M 56.66M 51.16M 56.13M 62.67M 66M 47.36M 40.16M 44.93M 44.16M 47.8M 39.09M 31.25M 29.45M 50.78M 27.83M 27.18M
    Research and Development Revenue Growth -9.43% -0.95% +2.88% -7.59% +12.03% +10.47% +9.77% +15.91% +7.06% +6.97% -16.38% +10.22% +6.29% +73.29% -16.50% +16.60% -0.35% -8.34% -11.58% +21.95% +28.01% +3.79% +6.09% +10.74% -8.86% -10.43% -5.04% +39.34% +17.94% -10.62% +1.74% -7.61% +22.27% +25.08% +6.10% -42.00% +82.46% +2.40% n/a

    Create Price Alert on JAZZ

    Your price alert will notify you when the stock price is above 117.19.

    Add to Watchlist